PDCD1 and non-small cell lung carcinoma: IC inhibitors (ICIs) such as anti-PD-1 or anti-PDL1 antibodies have shown promising results in the treatment of various cancers like unresectable or metastatic melanoma, renal cancer, metastatic non-small cell lung cancer (NSCLC), and more recently, Hodgkin’s lymphoma and urothelial carcinoma (8–14).